Post by AATec Medical

Our CEO, Dr. Rüdiger Jankowsky, will be at Bio€quity Europe 2026 in Prague, May 4–6. We look forward to connecting with investors, partners, and industry leaders as we advance ATL-105, our inhaled proprietary recombinant alpha-1 antitrypsin candidate. It is designed to address major respiratory diseases through a multimodal mechanism combining anti-inflammatory, tissue-protective, and anti-infective effects. We are currently preparing ATL-105 for its first clinical study in our lead indication, non-CF bronchiectasis, a chronic and debilitating respiratory disease affecting millions of people worldwide. Book a meeting or reach out to us directly to learn more.

Video Content